Navigation Links
18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkin's Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
Date:9/15/2009

s Control 6.9 months 6.9 months P Value 0.54 (HR = 0.88) 0.3 (HR = 0.82)

"We continue to be impressed by the durability of responses in the pixantrone treatment arm which seemed to improve during the study follow up period, compared to the standard chemotherapy recipients - whose responses and duration of response are largely unchanged from the initial assessment period," noted James A. Bianco, M.D., Chief Executive Officer of CTI. "We are also encouraged by the increase in the overall survival estimates, especially among those patients whose histologic diagnosis was verified by independent pathologists where 40% of pixantrone recipients were alive, compared to 27% for standard chemotherapy at the 1 year landmark period. We plan to submit these updated safety and efficacy data to our NDA as part of the 120 Day update."

The FDA typically receives updated clinical study data 120 days following the initial NDA submission.

The most common (incidence greater than or equal to 20%) adverse reactions reported for pixantrone-treated subjects were neutropenia, infection, anemia, leucopenia, thrombocytopenia, asthenia, pyrexia, and cough.

Pixantrone has been accepted for standard review by the Food & Drug Administration (FDA), with fast track status with a Prescription Drug User Fee Act (PDUFA) date of April 23, 2010.

           BioCentury's NewsMakers in the Biotech Industry Conference
                CTI Presentation: Wednesday, September 16, 2009
       10:30 a.m. Eastern /7:30 a.m. Pacific /6:30 p.m. Central European
             Audio webcast with slides at www.celltherapeutics.com

About the EXTEND (PIX301) Clinical Trial

The EXTEND clinical trial is a phase III single agent trial of pixantrone for patients with relapsed or refractory, aggressive nonHodgkin's lymphoma who recei
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
3. Alimera Sciences Announces Presentation of Data From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study at ARVO 2009 Annual Meeting
4. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
5. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
6. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
7. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
8. Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
9. Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
10. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
11. 12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... N.Y. , July 2, 2015  Before you head ... ahead so you can stay safe and healthy. Take steps ... #summersafety. Infographic http://nyackhospital.org/summersafety Protect Your Skin ... from the sun can increase your risk of skin cancer. ... shade as much as possible, especially during midday hours. Wear ...
(Date:7/2/2015)... According to a new market research report " ... Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, Tinnitus, Alzheimer,s, Epilepsy, Ischemia, ... the global Neuromodulation Market is estimated at $3.65 Billion in ... at a CAGR of 11.2% during the forecast period. ... market data T ables and 32 ...
(Date:7/2/2015)... , July 2, 2015   EVO Aesthetic ... the leading provider for non-invasive aesthetics in ... tattoo removal treatments with the Astanza Duality laser. The ... well being through various medical and laser procedures. Their ... unwanted ink a clear solution to their tattoo regret. ...
Breaking Medicine Technology:First Aid Summer Survival Tips from Nyack Hospital 2First Aid Summer Survival Tips from Nyack Hospital 3Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2
... , ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. ... medical countermeasures against biological and chemical threats, announced today ... demonstrating the effectiveness of Valortim® in an inhalation anthrax ... The data are being presented during an oral session ...
... , BILLERICA, Mass., Dec. 4 ... (Nasdaq: VOLC ), today announced the initial development and ... OCT imaging. Axsun believes this proprietary optical engine design ... of laser-based designs for swept source OCT light sources. ...
Cached Medicine Technology:PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5
(Date:7/2/2015)... OR (PRWEB) , ... July 02, 2015 , ... Hand ... During the current summer flu season, according to fresh water advocate and radio host ... on the hands. Kleyne cautions that for maximum effectiveness, hand sanitizers must be applied ...
(Date:7/2/2015)... LENEXA, Kan. (PRWEB) , ... July 02, 2015 ... ... firm dedicated exclusively to healthcare providers, has been retained to lead a national ... One of the top executive search firms in the healthcare industry, B. E. ...
(Date:7/2/2015)... ... ... Throughout the month of April, Casey’s General Stores invited customers to give ... 7, Casey’s General Stores Chairman and CEO, Bob Myers, will present a check to ... nonprofit dedicated to restoring a sense of self, restoring the family unit, and restoring ...
(Date:7/2/2015)... ... 2015 , ... AvePoint Public Sector, Inc., a wholly owned subsidiary ... today announced it was named the recipient of the 2015 GTRA ConVurge Tech Award ... by the Government Technology Research Alliance (GTRA), was presented June 29 during the ConVurge ...
(Date:7/2/2015)... ... July 02, 2015 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it has made two ... is the new General Manager at Catalent’s Schorndorf facility, which provides large scale, ...
Breaking Medicine News(10 mins):Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 2Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 2Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 4Health News:Catalent Makes Two Key European Appointments in Oral Dose Manufacturing 2
... people with skin care information from their most ... insights are provided by skin care experts with ... The content is written by experts in skin ... advice. Key portions of the service include information ...
... Slimband employees successfully competed in the 19th Annual Canada Life CN Tower Climb ... ... 22, 2009-- A team of Slimband employees successfully competed in the ... April 16th. The CN Tower Climb is a demanding competition in which ...
... continues to follow her treacherous sister Notre Dame ... 22 Georgetown University continues to follow ... with award, pro-lifers to protest.On Wednesday, April 22, starting ... will protest at Georgetown Law Center, McDonough Hall, 600 ...
... 21 When Gundersen Lutheran Health System set out to ... 2 percent decrease that,s common at healthcare facilities. Instead, they,re ... than two years. That,s 9,600 metric tons of carbon dioxide ... of removing 1,631 cars from the road. The La Crosse, ...
... OKLAHOMA CITY, April 21 Costs to families and ... to the neighborhood gas station. That is why it ... affordable and accessible to all Oklahomans. Holding down the ... task, but controlling costs is a challenge we can ...
... Pharmos Corporation (Pink Sheets: PARS) announced today that ... and warrants. At the closing, the Company issued ... an additional 18,000,000 shares of common stock for an ... of the warrants, which have a five-year term, is ...
Cached Medicine News:Health News:Beauty-Doctors Website Provides Dermatologist-Authored Skin Care Information from Experts 2Health News:Slimband™ Team Competes in CN Tower Climb and Helps Fight Against Global Warming 2Health News:Anti Abortion Protesters will be at VP Biden Award at Georgetown Law School 2Health News:Innovative Program Will Help Lead Health System to Energy Independence by 2014 2Health News:Refuting Misconceptions About Health Insurance Mandates 2Health News:Pharmos Completes Private Placement - Raises $1.8 Million 2Health News:Pharmos Completes Private Placement - Raises $1.8 Million 3
Conducting disposable tips provide cross-contaminationfree pipetting for sensitive applications such as PCR setup....
300 L, Bulk Recommended for 250 and 300 L pipettes. Can also be used with 20, 25, 50, 100 and 200 L pipette...
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
... to order tips. Each box contains 10,000 ... available in easy-to-open, re-sealable Bulk Packs of ... sealed with a tamper-proof strip which can ... Gilsons Diamond Tips. Bulk Packs are closed ...
Medicine Products: